Distal chromosome 1q aberrations and initial response to ibrutinib in central nervous system relapsed mantle cell lymphoma
Relapse involving the central nervous system (CNS) is an infrequent event in the progression of mantle cell lymphoma (MCL) with an incidence of approximately four percent. We report four cases of MCL with CNS relapse. In three of the four patients a large chromosomal copy-number alteration (CNA) of...
Main Authors: | Marcus Høy Hansen, Karen Juul-Jensen, Oriane Cédile, Stephanie Kavan, Michael Boe Møller, Jacob Haaber, Charlotte Guldborg Nyvold |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Leukemia Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048921000224 |
Similar Items
-
Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice
by: Vladimir I. Vorobyev, et al.
Published: (2021-07-01) -
Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice
by: VI Vorob’ev, et al.
Published: (2019-03-01) -
Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report
by: Danuta Krasowska, et al.
Published: (2020-09-01) -
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
by: Michael Wang, et al.
Published: (2017-11-01) -
Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
by: Young‐Woo Jeon, et al.
Published: (2019-11-01)